戻る
Ligand Pharmaceuticals Inc (LGNZZ)価格
LGNZZ 株価推移チャート
LGNZZ 収入
Ligand Pharmaceuticals Inc
$0.07
-2.77%
$0
終値： Feb 11, 16:00:00 GMT-5
$0.07
0%
$0
アフターマーケット：Feb 11, 20:00:00 GMT-5
最新の利益結果: Q3 '25
報告済み: 2025-11-06
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
LGNZZの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Ligand Pharmaceuticals Inc LGNZZの前四半期の収益はどうでしたか？
Ligand Pharmaceuticals Incの収益見積もりはいくらですか？
Ligand Pharmaceuticals Incの収益品質スコアはどれくらいですか？
Ligand Pharmaceuticals Incはいつ収益を報告しますか？
Ligand Pharmaceuticals Incの予想収益はいくらですか？
Ligand Pharmaceuticals Incは収益予想を上回りましたか？
主要データ
前終値
$0.072
始値
$0.07
当日レンジ
$0.07 - $0.07
52週レンジ
$0.07 - $0.17
取引高
3.0K
平均取引高
50.0K
1株当たり利益(TTM)
2.78
配当利回り
--
時価総額
$1.3M
LGNZZとは何ですか？
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. The company is headquartered in Jupiter, Florida and currently employs 68 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.